drugset / Trial / NCT02466399

POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma

NCT02466399

Phase 2 Completed 80 enrolled Peregrine Ophthalmic
RandomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, randomized, multi-center, active-controlled parallel-comparison of POLAT-001 to latanoprost ophthalmic solution in patients with ocular hypertension and primary open-angle glaucoma.

Timeline

Start
2015-07
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost Small molecule 0.005 % Other
Comparator Latanoprost Small molecule

Indications